Nephrology · Clinical Calculator · Bone & Mineral

Mineral Metabolism Workbench Phosphate Handling · PTH Trends · Calcium Ledger

Six browser-local tools that keep arithmetic separate from interpretation: renal phosphate handling (FEPO₄, TRP, TmP/GFR), an assay-aware CKD-MBD trend dashboard, an elemental calcium ledger, a mineral unit converter, an IV iron and phosphate review aid, and an antiresorptive mineral-safety planner.

Published: References: 10 Read time:

← All calculators & tools  ·  Related guide →

Last Reviewed:
Instructions
  1. Phosphate handling: enter paired serum and urine phosphate and creatinine with a unit for each, then the specimen context. Phosphate pairs and creatinine pairs may use different units; the tool normalizes them.
  2. Trend dashboard: add each result with its date, analyte, unit, assay or laboratory name and that laboratory’s limits. PTH is standardized only when the assay ULN is entered.
  3. Calcium ledger: list each calcium-containing product with its elemental calcium per unit from the verified label.
  4. Review aids: the IV iron and antiresorptive tools document and prompt; they do not score or decide.

Everything runs in your browser. Nothing is stored, sent to analytics or placed in the address bar. Do not enter names, hospital numbers or other identifiers.

When to Use — and What These Tools Do Not Do

Use with Novel Regulators and Functions in Mineral Metabolism for adults with CKD G3a–G5D and for hypophosphatemia work-up. Arithmetic is versioned in MM-CORE v1.0.0; interpretive notes come from a separate, sourced rule set (MM-RULES v0.1.0-draft) that is marked as a draft pending clinical sign-off.

⚠️

Deliberately excluded

No FGF23/Klotho score or ratio, no activin A fracture predictor, no T50 inferred from calcium and phosphate, no “mineral stress index,” no automatic drug selection or dose change, no bone-turnover diagnosis, no “MBD controlled” badge, and no individual probability derived from trial or cohort rates. Calcium is never auto-adjusted for albumin, and total and ionized calcium are never converted into each other.

Renal Phosphate Handling — FEPO₄, TRP, TmP/GFR

Fractional excretion of phosphate (FEPO₄), tubular reabsorption of phosphate (TRP) and the tubular maximum for phosphate reabsorption per glomerular filtration rate (TmP/GFR) by the Kenny–Glen algorithm (Payne, 1998; Barth et al., 2000). Designed for the question “is the kidney conserving phosphate appropriately when serum phosphate is low?”

Paired sample

Urine creatinine is often reported in mmol/L.

Specimen and patient context (drives applicability limits, not the arithmetic)

⚕ FEPO₄ (%) = 100 × (UP × SCr) ÷ (SP × UCr); TRP = 1 − FEPO₄/100; TmP/GFR = TRP × SP if TRP ≤ 0.86, else SP × 0.3 × TRP ÷ (1 − 0.8 × TRP). TmP/GFR keeps the serum phosphate unit. A low TmP/GFR does not identify the responsible hormone.

Assay-Aware CKD-MBD Trend Dashboard

Small-multiple charts for total calcium, ionized calcium, phosphate, intact PTH (iPTH), alkaline phosphatase (ALP) and 25-hydroxyvitamin D. Lines break wherever the assay or unit changes; change is shown only against the prior comparable sample. PTH is plotted as a multiple of the assay’s upper limit of normal (ULN) when every PTH row has one.

CollectedAnalyteValueUnitAssay / labLower limitUpper limit (ULN)

Treatment events (drawn as markers; never used to compute anything)

⚕ PTH ratio = PTH ÷ assay ULN (no ratio when the ULN is missing or ≤ 0). The approximately 2–9 × ULN band (KDIGO 2017, 4.2.3, grade 2C) is drawn only for CKD G5D and does not imply appropriate bone turnover.

Elemental Calcium & Treatment-Burden Ledger

Sums documented prescribed oral elemental calcium: Σ (elemental mg per unit × units per dose × doses per day), and counts tablets per day. Diet and dialysate calcium are recorded separately and never added in.

Product (verified label)CategoryElemental Ca mg / unitUnits / doseDoses / dayAdherence

Label shows only the salt mass?

Recorded separately

Mineral Unit Converter

Same-analyte conversions only. Total and ionized calcium are different measurements and are never converted into each other.

Result

⚕ Constants: phosphate 1 mg/dL = 0.3229 mmol/L; total calcium 1 mg/dL = 0.2495 mmol/L; ionized calcium 1 mmol/L = 4.008 mg/dL; creatinine 1 mg/dL = 88.4 µmol/L; PTH 1 pmol/L = 9.43 pg/mL; 25-hydroxyvitamin D 1 ng/mL = 2.496 nmol/L; magnesium 1 mg/dL = 0.4114 mmol/L. Rounded for display only.

IV Iron & Hypophosphatemia Review Aid

Captures formulation, exposure, phosphate results, symptoms and competing causes, then shows a formulation-specific evidence card and review prompts. There is no risk score and no replacement regimen.

Symptoms
Competing causes

Antiresorptive Mineral-Safety Planner

Documents the mineral assessment and calcium-monitoring plan before an antiresorptive in CKD. It never returns “eligible,” selects a drug or sets a dose.

Formulae, Validation & Evidence

Formulae

QuantityEquationSource
FEPO₄100 × (UP × SCr) ÷ (SP × UCr), each pair normalized to one unitPayne, 1998
TRP1 − FEPO₄/100; rejected if outside 0–1Payne, 1998
TmP/GFRTRP ≤ 0.86: TRP × SP · TRP > 0.86: SP × 0.3 × TRP ÷ (1 − 0.8 × TRP)Kenny–Glen algorithm; Barth et al., 2000
PTH ratioPTH ÷ assay ULN; band ~2–9 × ULN for G5D onlyKDIGO 2017 (4.2.3, 2C); Souberbielle et al., 2006
Elemental calciumΣ elemental mg/unit × units/dose × doses/day; carbonate 40.0%, anhydrous acetate 25.3% by molar massChemistry; verify against label

Validation status

ModuleArithmeticInterpretation
Phosphate handlingGolden fixtures pass to 1e-6 (FE 10% / TRP 0.90 / TmP 1.92857; FE 20% / TRP 0.80 / TmP 1.60); boundary TRP 0.86 uses the ≤ branch; SI and mixed-unit equivalence; invalid-input pathsDraft v0.1.0 — adult Barth ranges only; pending nephrologist sign-off
Trend dashboardPTH 540 ÷ 65 = 8.3077; 540 ÷ 88 = 6.1364; no ratio for missing/zero ULN; break and no delta across assaysG5D band only; no turnover inference
Calcium ledger200 × 2 × 3 = 1,200 mg/day; duplicate and negative-value checksNone (documentation only)
IV iron, antiresorptiveNo computation beyond unit conversionEvidence cards; monitoring schedules not activated pending label verification

Arithmetic fixtures are not clinical validation. 54 automated unit tests (MM-CORE v1.0.0) passed at publication.

Important: These tools are educational aids for clinicians. They do not diagnose, decide treatment or dose, or predict individual risk. Use local protocols, current product labels and specialist advice.
References 10 sources
  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney International Supplements, 7(1), 1–59. https://doi.org/10.1016/j.kisu.2017.04.001
  2. Wolf, M., Rubin, J., Achebe, M., Econs, M. J., Peacock, M., Imel, E. A., Thomsen, L. L., Carpenter, T. O., Weber, T., Brandenburg, V., & Zoller, H. (2020). Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: Two randomized clinical trials. JAMA, 323(5), 432–443. https://doi.org/10.1001/jama.2019.22450
  3. Schaefer, B., Tobiasch, M., Viveiros, A., Tilg, H., Kennedy, N. A., Wolf, M., & Zoller, H. (2021). Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—A systematic review and meta-analysis. British Journal of Clinical Pharmacology, 87(5), 2256–2273. https://doi.org/10.1111/bcp.14643
  4. Bellos, I., Frountzas, M., & Pergialiotis, V. (2020). Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: A network meta-analysis. Transfusion Medicine Reviews, 34(3), 188–194. https://doi.org/10.1016/j.tmrv.2020.07.002
  5. Desgagnés, N., King, J. A., Kline, G. A., Seiden-Long, I., & Leung, A. A. (2025). Use of albumin-adjusted calcium measurements in clinical practice. JAMA Network Open, 8(1), e2455251 (corrected March 18, 2025). https://doi.org/10.1001/jamanetworkopen.2024.55251
  6. Bird, S. T., Smith, E. R., Gelperin, K., Jung, T. H., Thompson, A., Kambhampati, R., Lyu, H., Zhao, H., Zhao, Y., Zhu, Y., Easley, O., Niak, A., Wernecke, M., Chillarige, Y., Zemskova, M., Kelman, J. A., & Graham, D. J. (2024). Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA, 331(6), 491–499. https://doi.org/10.1001/jama.2023.28239
  7. U.S. Food and Drug Administration (FDA). (2024, January 19). FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab) [Drug safety communication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease
  8. Souberbielle, J.-C., Boutten, A., Carlier, M.-C., Chevenne, D., Coumaros, G., Lawson-Body, E., Massart, C., Monge, M., Myara, J., Parent, X., Plouvier, E., & Houillier, P. (2006). Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney International, 70(2), 345–350. https://doi.org/10.1038/sj.ki.5001606
  9. Payne, R. B. (1998). Renal tubular reabsorption of phosphate (TmP/GFR): Indications and interpretation. Annals of Clinical Biochemistry, 35(2), 201–206. https://doi.org/10.1177/000456329803500203
  10. Barth, J. H., Jones, R. G., & Payne, R. B. (2000). Calculation of renal tubular reabsorption of phosphate: The algorithm performs better than the nomogram. Annals of Clinical Biochemistry, 37(1), 79–81. https://doi.org/10.1258/0004563001901371
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

All Calculators Related Guides